Suspecting and Diagnosing ATTR Amyloidosis

Morie A Gertz, MD, MACP
Consultant – Division of Hematology, Department of Internal Medicine
Mayo Clinic
Professor of Medicine
Mayo Clinic College of Medicine and Science
Rochester, Minnesota

The target audience for this initiative is physicians and other providers, including nurse practitioners and physician assistants, who may encounter patients in their practice with undiagnosed amyloid transthyretin (ATTR) amyloidosis.

Learn about ATTR Amyloidosis – including how to shorten individuals’ diagnostic journey and the time till they access treatment which might improve their quality of life or even prevent disease progression – through these brief (15 minute) courses that are certified for CME/CNE credit:

Provided by
Support for this activity has been made possible through educational grants from Akcea Therapeutics and Alnylam Pharmaceuticals.